Altus Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Altus Pharmaceuticals
Starting stock price: $19.19
Ending stock price: $5.18
Percent Change: -73.01%

Details: In July Altus lost orphan drug status for its experimental pancreatic insufficiency therapy; the FDA said the number of patients with the condition exceeds the 200,000 mark required for an orphan drug. But the real blow came in December when Genentech return the North American rights to ALTU-238, a growth hormone. Altus is looking for another partner for the drug.

More News:
Altus shares dive as Genentech hands back drug rights. Report
Altus loses orphan drug status. Report
Altus inks $140M pact for human growth hormone. Report
Altus stock plunges on clinical trial delay. Report

Altus Pharmaceuticals - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity